Product Pipeline

PTG-100: α4β7 Integrin Specific Oral Peptide Antagonist for IBD

Latest News

July 16, 2015

Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs Into Clinical Development read more

December 4, 2014

Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015 read more

November 5, 2014

Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors read more

Upcoming Events

September 28 - October 21, 2015

Boulder Peptide Symposium 2015
Boulder, CO

October 20-21, 2015

BIO Investor Forum
San Francisco, CA

November 2-4, 2015

BioEurope 2015 - 21st Annual International Partnering Conference
Munich, Germany